Clinical Trial Update: Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839 [Phase 2]

View source ↗

Summary

Phase 2 trial update for Vatelizumab in relapsing-remitting multiple sclerosis; efficacy and safety data in patients who completed study DRI13839 are reported, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Vatelizumab (Vatelizumab)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Relapsing-remitting Multiple Sclerosis | Phase 2 | Status: TERMINATED